Cevimeline (Saligren) is an oral dryness-relieving medication approved in Japan for specific patient populations. It is particularly indicated for patients with Sjögren's syndrome, who experience significant reduction in salivary secretion that may lead to a series of issues such as dysphagia, oral discomfort and increased risk of dental caries.

What are the indications for Cevimeline (Saligren)?

Relief of oral dryness in patients with Sjögren's syndrome

Sjögren's syndrome is a chronic autoimmune disease that primarily affects exocrine glands, especially the salivary and lacrimal glands, leading to dry mouth and dry eyes.

Through its pharmacological action, cevimeline can specifically stimulate the residual function of the salivary glands in patients, thereby alleviating the discomfort caused by dry mouth.

It is important to note that this medication is not indicated for dry mouth caused by other factors (e.g., drug side effects, simple aging, dehydration, etc.).

A definitive diagnosis of Sjögren's syndrome by a physician is mandatory before use.

Specifications and Characteristics of Cevimeline (Saligren)

Specifications and Composition

The common commercial specification of cevimeline is Saligren Capsules 30mg.

Active ingredient: Each capsule contains 31.15mg of cevimeline hydrochloride hydrate, equivalent to 30mg of cevimeline hydrochloride.

Excipients: The capsules also contain lactose hydrate, sodium lauryl sulfate and other auxiliary materials.

Physical Characteristics

Dosage form and color: This product is a hard capsule with a shell composed of yellow and white parts.

Contents: The capsule is filled with a white powder.

Shape and identification code: The capsule is Size 3, with a weight of approximately 0.27 grams. Identification codes such as "NK1182" are usually printed on the packaging to facilitate accurate identification and traceability during circulation.

Storage Method for Cevimeline (Saligren)

Storage Conditions

Store away from direct sunlight, high temperature (e.g., near heating radiators) or excessive humidity (e.g., in the bathroom).

Shelf life: 3 years from the date of manufacture. Patients shall use the medication within the expiration date indicated on the package.

Special Precautions

This product is packaged in PTP aluminum-plastic blisters. When taking the medication, the capsule must be completely pressed out from the blister; do not swallow the capsule together with the aluminum foil blister, as the sharp edges of the aluminum foil may injure the esophagus and cause severe complications.

For non-PTP packaging (e.g., bottle packaging), protect from moisture after opening the cap and tightly reseal the bottle after each use to keep the medication dry.